tert-Butyl 4-(6-Amino-3-pyridyl) piperazine-1-Carboxylate CAS 571188-59-5 Purity >99.0% (HPLC)
Ruifu Chemical Supple Palbociclib Intermedia:
Palbociclib CAS 571190-30-2
5-Bromo-2,4-Dichloropyrimidines CAS 36082-50-5
5-Bromo-2-Chloro-N-Cyclopentylpyrimidin-4-Amine CAS 733039-20-8
tert-Butyl 4-(6-Nitropyridin-3-yl) piperazine-1-Carboxylate CAS 571189-16-7
tert-Butyl 4-(6-Amino-3-pyridyl) piperazine-1-Carboxylate CAS 571188-59-5
6-Bromo-2-Chloro-8-Cyclopentyl-5-Methylpyrido-[2,3-d]pyrimidin-7(8H)-one CAS 1016636-76-2
2-Chloro-8-Cyclopentyl-5-Methyl-8H-pyrido[2,3-d]pyrimidin-7-one CAS 1013916-37-4
Nomen chemicum | tert-Butyl 4-(6-Amino-3-pyridyl) piperazine-1-Carboxylate. |
Synonyma | 4-(6-Amino-3-Pyridyl) -1-Boc-Piperazine;1-Boc-4-(6-Amino-3-Pyridyl) piperazine;4-(6-Amino-3-pyridyl) piperazinum 1-Carboxylic Acidum tert-Butyl Ester;1-tert-butoxycarbonyl-4-(6-Amino-3-pyridyl)piperazinum;Palbociclib immunditia 10;Palbociclib Medium 1;Otava-Bb 1207229 |
CAS Number | 571188-59-5 |
CATTUS Number | RF-PI1848 |
Stock Status | In Stock, Productio Ascendite ad Tons |
Formulae hypotheticae | C14H22N4O2 |
M. Pondus | 278.35 |
Liquescens punctum | 131.0 ad 135.0℃ |
Brand | Ruifu Chemical |
Item | Specifications |
Aspectus | Off-White ad lux Yellow pulveris |
Indentification ab HPLC | Retentionis tempus principalis culminis in HPLC debet concordare cum regula vexillum |
Puritas / Analysis Methodus | >99.0% (HPLC) |
Damnum in Siccatio | <0.50% |
Residere in Ignition | <0.20% |
Totalis immunditias | <1.00% |
Test Standard | Enterprise Standard |
Consuetudinem | Medium Palbociclib (CAS: 571190-30-2) |
sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore
tert-Butyl 4-(6-Amino-3-pyridyl) piperazinum 1-carboxylatum (CAS: 571188-59-5) adhibetur ut intermedium pharmaceuticum.Est medium Palbociclib (CAS: 571190-30-2).Palbociclib medicamentum est ad curationem carcinomatis ER-positivi et HER2-negativi carcinomatis effecti.Palbociclib inhibitor selectivorum cyclini-dependens kinases CDK4 et CDK6 est.